https://doi.org/10.31288/oftalmolzh201353033

Application of aflibercept before vitrectomy in patients with proliferative diabetic retinopathy (pilot study)

Umanets NN, Rozanova ZA, Korol AR, Zavodnaya VS

 SI «The Filatov Institute of Eye Diseases and Tissue Therapy NAMS of Ukraine», Odessa

E-mail dios.86@mail.ru

Introduction. The choice of anti-VEGF agent for rapid and complete obliteration of neovascularisation in the surgery of severe proliferative diabetic retinopathy is not yet completely resolved.

The aim of this study was to investigate the possibility of intravitreal aflibercept before vitrectomy in patients with severe proliferative diabetic retinopathy. 

Materials and methods. There were 5patients (5 eyes) with severe proliferative diabetic retinopathy complicated by tractional retinal detachment. 20 G (3 cases), 25 G (2 cases) vitrectomy was performed on all patients 3 days after intravitreal injection of aflibercept (0.05ml, 2mg)

Results. In 5 cases of proliferative diabetic retinopathy with epiretinal membranes and traction retinal detachment intravitreal aflibercept (0.05 mL, 2 mg) resulted in the obliteration of newly formed blood vessels of epiretinal membranes within 3 days after injection, thus avoiding intra-andpostoperative bleeding during vitrectomy.

Conclusion. Aflibercept is a promising anti-VEGF agent for preoperative intravitreal injection to patients with proliferative DRP before vitrectomy.

Key words: severe diabetic retinopathy, aflibercept, vitrectomy.

References

1.Zhmurik DV. Applications of heavy fluid in vitreoretinal surgery. Oftalmol Zh. 2012; 2: 68- 74.
Crossref

2.Ilyukhin PA. Application of antiangiogenic factors in surgi-cal treatment of profilerative diabetic retinopathy. Author's abstract..Cand. of Med. Sc. Moscow; 2012. 18 p.

3.Rodin SS, Aslanova VS. Bevacizumab (Avastin) in the complex surgical treatment of patients with proliferative stage of diabetic retinopathy. Ukrainskii med. Almanakh. 2008; 3: 126-8.

4.Shkvorchenko DO, Levina LV. Retinotomy and retinec-tomy in the treatment of prolifrative diabetic retinopathy complicated with anterior prolifertive vitreoretinopathy. All Russian scientific practical conference of ophthalmologists. Moscow; 2006. 205-10.

5.Umanets NN, Rozanova ZA. Complex surgical treatment of patients with late forms of proliferative diabetic reti-nopathy. Scientific practical conference of ophthalmologists with international participation «Filatov Memorial Lectures», 24- 25 May, 2012; Odessa. 214-5

6.Abu-Yaghi NE, Bakri SJ. The use of antivascular endothe-lial growth factor agents in the perioperative period in diabetic vitrectomy. Middle East Afr Ophthalmol. 2012; Jan 19 (1): 83-7.
Crossref

7.Ahmadieh H, Shoeibi N, Entezari M, Monshizadeh R. Intravitreal bevacizumab for prevention of early postvitrecto-my hemorrhage in diabetic patients: a randomized clinicaltrial. Ophthalmology. 2009; 116: 1943-8. costs for the U. S. // Diabetes Care. — 2009. — Vol. 32 — P. 2225- 2229.
Crossref

9.Joondeph B. C. Hemostatic effects of air versus fluid in dia-betic vitrectomy/ Joondeph B. C., Blankenship G. W. // Ophthalmology. — 1989. — Vol. 96. — P.1701- 1707 8.Huang ES, Basu A, O'Grady M, Capretta JC. Projecting the future diabetes population size and related costs for the U. S. Diabetes Care. 2009; 32: 2225- 9.

9.Joondeph BC, Blankenship GW. Hemostatic effects of air versus fluid in diabetic vitrectomy. Ophthalmology. 1989; 96: 1701- 7.

10.Koutsandrea CN, Apostolopoulos MN, Chatzoulis DZ et al. Hemostatic effects of SF6 after diabetic vitrectomy for vitreous hemorrhage. Acta Ophthalmol Scand. 2001; 79: 34-8.
Crossref

11.Oyakawa RT, Schachat AP, Michels RG et al. Complica-tions of vitreous surgery for diabetic retinopathy. Intraop-erative complications. Ophthalmology. 1983; May 90(5): 517-21.
Crossref

12.Pokroy K, Desai UR, Du E. Bevacizumab prior to vitrec-tomy for diabetic traction retinal detachment. Eye (Lond). 2011; Aug 25(80): 989- 97.
Crossref

13.Ramezani AR, Ahmadieh H, Ghaseminejad AK et al. Effect of tranexamic acid on early postvitrectomy diabetic haemorrhage; a randomised clinical trial. Br J Ophthalmol. 2005; 89: 1041-4.
Crossref

14.Yang CM, Yeh PT, Yang CH. Intavitreal long-acting gas in the prevention of early postoperative vitreous hemorrhage in diabetic vitrectomy. Ophthalmology. 2007; 114: 710-5.
Crossref